Literature DB >> 21616149

Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation.

Tatsu Tanabe1, Hideki Ishida, Shigeru Horita, Yutaka Yamaguchi, Hiroshi Toma, Kazunari Tanabe.   

Abstract

BACKGROUND: Few studies have investigated the changes in the antigenicities of the transplanted organs after transplantation.
METHODS: We examined, by immunohistochemical assay, the changes in expression of the blood-type antigens on the transplanted kidneys over the long-term after ABO-incompatible kidney transplantation with A- or B-antigen incompatibility (blood type A to B and B to A). The subjects were six patients, including one case with graft loss, who had received ABO-incompatible kidney allografts more than ten years previously. As normal controls, four cases of ABO-compatible transplantation during the same period, including two recipient/donor pairs each with blood group A1 and blood group B were enrolled.
RESULTS: Expression of the blood-type A or B antigens decreased gradually to 91.8% during the first three months after transplantation, 85.8% during the first five years, 64.1% during the first ten years, and 57.6% over ten years after transplantation on average in ABO-incompatible transplant recipients. In one patient with graft loss due to severe antibody-mediated rejection, the donor's type B blood-type antigens on the transplanted graft had changed but partially to the recipient's blood-type A antigen by 2582days after the transplantation, suggestive of the occurrence of blood-type chimerism on the endothelium. In ABO-compatible transplant recipients, such changes in expression were not observed. The average percentage of blood-type antigen-positive vessels at more than ten years after the renal transplantation was 99.8%.
CONCLUSIONS: Decrease in the expression of the donor's blood-type antigen on the endothelium of the graft has been considered as one of the mechanisms underlying the accommodation occurring over the long-term after ABO-incompatible kidney transplantation. On the other hand, establishment of antigenic chimerism on the graft endothelium could be one of the hallmarks of the immunological reaction associated with antibody-mediated rejection.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616149     DOI: 10.1016/j.trim.2011.05.002

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  13 in total

1.  GPIHBP1 autoantibody syndrome during interferon β1a treatment.

Authors:  Jun Eguchi; Kazuya Miyashita; Isamu Fukamachi; Katsuyuki Nakajima; Masami Murakami; Yuko Kawahara; Toru Yamashita; Yasuyuki Ohta; Koji Abe; Atsuko Nakatsuka; Mai Mino; Satoru Takase; Hiroaki Okazaki; Robert A Hegele; Michael Ploug; Xuchen Hu; Jun Wada; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2018-10-24       Impact factor: 4.766

2.  A case of nearly mistaken AB para-Bombay blood group donor transplanted to a group 'O' recipient.

Authors:  Natavudh Townamchai; Phandee Watanaboonyongcharoen; Wiwat Chancharoenthana; Yingyos Avihingsanon
Journal:  BMJ Case Rep       Date:  2014-10-31

3.  Blood Group A antigen expression on cardiac endothelium is highly individualized: possible implications for transplantation.

Authors:  Eric A Gehrie; Justin M Cates; Hui Nian; Sandy J Olson; Pampee P Young
Journal:  Cardiovasc Pathol       Date:  2013-01-04       Impact factor: 2.185

4.  Computed tomography findings in ABO-incompatible living donor liver transplantation recipients with biliary strictures.

Authors:  Sang Hyun Choi; Kyoung Won Kim; So Yeon Kim; Jin Sil Kim; Jae Hyun Kwon; Gi-Won Song; Sung-Gyu Lee
Journal:  Eur Radiol       Date:  2018-01-02       Impact factor: 5.315

5.  ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange.

Authors:  Julie M Yabu; Magali J Fontaine
Journal:  J Clin Apher       Date:  2015-03-05       Impact factor: 2.821

Review 6.  Strategies to overcome the ABO barrier in kidney transplantation.

Authors:  Georg A Böhmig; Andreas M Farkas; Farsad Eskandary; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2015-09-01       Impact factor: 28.314

7.  Identification of an activation-related protein in B cells in the ABO incompatible condition.

Authors:  Jingsong Cao; Cong Chen; Luogen Liu; Yunsheng Zhang; Hong Zhou; Jianhua Xiao; Yi Wang
Journal:  Exp Ther Med       Date:  2019-11-22       Impact factor: 2.447

8.  Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes.

Authors:  Olivia R Blume; Sarah E Yost; Bruce Kaplan
Journal:  J Transplant       Date:  2012-03-24

Review 9.  Desensitization for solid organ and hematopoietic stem cell transplantation.

Authors:  Andrea A Zachary; Mary S Leffell
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

10.  The influence of HK2 blood group antigen on human B cell activation for ABOi-KT conditions.

Authors:  Jingsong Cao; Luogen Liu; Yunsheng Zhang; Jianhua Xiao; Yi Wang
Journal:  BMC Immunol       Date:  2017-12-16       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.